Back to top
more

VolitionRX Limited (VNRX)

(Delayed Data from AMEX)

$0.62 USD

0.62
74,256

-0.03 (-4.29%)

Updated Dec 26, 2024 04:00 PM ET

After-Market: $0.62 0.00 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.35%
2Buy18.11%
3Hold9.74%
4Sell5.34%
5Strong Sell2.80%
S&P50011.41%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 249)

Industry: Medical - Biomedical and Genetics

Key Expected Earnings Data

Better trading starts here.

Report Date Period Ending Zacks Consensus Estimate Earnings ESP
03/24/2025

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.


Time: --
12/2024 $-0.06 0.00%

Earnings Summary

For their last quarter, VolitionRX Limited (VNRX) reported earnings of -$0.07 per share, in line with the Zacks Consensus Estimate. This reflects a breakeven earnings surprise. Look out for VNRX's next earnings release expected on March 24, 2025. For the next earning release, we expect the company to report earnings of -$0.06 per share, reflecting a year-over-year increase of 45.45%.

Earnings History

*BMO: Before Market Open

*AMC: After Market Close

Price & Consensus

VNRX FAQs

VolitionRX Limited (VNRX) has announced they will report their next quarter earnings on March 24, 2025. For the next earning release, we expect the company to report earnings of $-0.06 per share, reflecting a year-over-year increase of 45.45%.

VolitionRX Limited has announced they will report their previous quarter earnings after the close of the market on March 24, 2025.

The Zacks Consensus Estimate for VolitionRX Limited (VNRX) for the quarter ending December 2024 is $-0.06 a share. We expect VolitionRX Limited (VNRX) to report earnings in line with the consensus estimate of $-0.06 per share

In the earnings report for the quarter ending in June 2024, VolitionRX Limited (VNRX) announced earnings of $-0.08 per share versus the Zacks Consensus Estimate of $-0.09 per share, representing a surprise of -11.11%.